GlassScriptPhysician profile
Melissa Prince
NPI 1700914199
$6,495.36
in general payments reported to CMS, 2019-2025
32 companies · $95.60 in 2025
The $95.60 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,727 · 2022: $1,866 · 2023: $2,482 · 2024: $325 · 2025: $95.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Consulting Fee: $900 · Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Consulting Fee | $900.00 |
| Food and Beverage | $803.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $2,286.78 | 2021-2023 | Tirosint |
| Insulet Corporation | $696.28 | 2021-2022 | |
| Zealand Pharma US, INC. | $540.35 | 2021-2022 | |
| Corcept Therapeutics | $488.01 | 2021-2024 | Korlym |
| Lilly USA, LLC | $486.32 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $212.74 | 2024-2025 | Evenity, Prolia |
| Abbott Laboratories | $163.92 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $141.59 | 2021-2022 | |
| Mannkind Corporation | $133.50 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $131.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $130.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.35 | 2021-2022 | |
| Novo Nordisk INC | $99.64 | 2021-2024 | Wegovy |
| Alexion Pharmaceuticals, INC. | $96.31 | 2021-2022 | |
| Abbvie INC. | $86.79 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.35 | 2021-2022 | |
| Medicure Pharma INC. | $75.39 | 2021-2023 | Zypitamag |
| Medtronic, INC. | $67.17 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $66.66 | 2021-2022 | |
| Clarus Therapeutics INC. | $57.03 | 2021 | |
| Horizon Therapeutics Plc | $54.46 | 2022 | |
| Dexcom, INC. | $46.66 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $43.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.38 | 2022 | |
| Amryt Pharma Holdings LTD | $28.11 | 2022 | |
| Intuity Medical INC | $26.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.44 | 2021 | |
| Alfasigma USA, INC. | $18.80 | 2021 | |
| Ascensia Diabetes Care US INC. | $17.12 | 2022 | |
| Amarin Pharma, INC. | $15.29 | 2022 | |
| Currax Pharmaceuticals LLC | $14.53 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.